Cash, Lights, Go: Shanghai Takes On Boston In Latest Policy Appeal To Biopharma
From R&D To Manufacturing Powerhouse?
Developers of antibodies, novel vaccines and cell and gene therapies are all slated to get funding support as Shanghai unleashes a flurry of incentives and policies to lead China’s push to become a global biopharma powerhouse.
You may also be interested in...
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.
Beneath booming healthcare financing and deal-making in Asia is a constant flow of ready capital, but there are also challenges that may present hurdles to Hong Kong overtaking Nasdaq as the premier site for listings in the sector, a recent summit heard.
A drug maker’s downfall prompts a new wave of regulatory crackdowns on accounting and audit fraud in China with broad implications across industry sectors.